Dyne Therapeutics

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / September 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Lost Money on Dyne Therapeutics, Inc.(DYN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK CITY, NY / ACCESSWIRE / September 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

(DYN) INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

NEW YORK--(BUSINESS WIRE)---- $DYN #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). The investigation concerns whether Dyne and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On September 3, 2024, Dyne issued a press release “announc[ing] new clinical data from its ongoing Phase 1/2 DEL.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Dyne Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - DYN

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors In Dyne Therapeutics, Inc. Are Invited To Join An Investigation For Possible Securities Related Infractions

Investors who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / September 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Dyne Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Dyne Therapeutics, Inc. (DYN)

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Dyne Therapeutics Inc May Have Committed Securities Fraud And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Levi & Korsinsky Announces an Investigation on Behalf of Dyne Therapeutics, Inc. (DYN) Shareholders Who May Have Been Affected by Fraud

Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

DYN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Dyne Therapeutics, Inc.

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm In Looking Into Dyne Therapeutics Inc. For Potential Securities Law Violations And Investors Can Reach Out

Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc.(DYN) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

DYN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Dyne Therapeutics, Inc. investment

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Dyne Therapeutics Inc May Have Defrauded The Public And Affected Stockholders Should Join The Schall Law Firm's Inquiry

DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

NEW YORK CITY, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation

Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building

Boeing

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs -

News for Dyne Therapeutics Stock (DYN)